DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award

The fiscal year 2026 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype. • The award focuses on clinical biomarkers and/or clinical outcomes, including the identification, development, and/or validation of promising biomarkers for ALS. • Applications may utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes. • Community Collaboration is an important element of the FY26 ALSRP COBA, and applicants will be expected to articulate how the proposed research question or study design was informed by the ALS lived experience community.